Abstract
Whole blood viscosity, plasma viscosity, erythrocyte deformability, and finger systolic pressure (FSP) were measured in ten patients with primary vasospastic (Raynaud's) disease before and after a controlled double-blind prospective trial involving dazoxiben (a thromboxane inhibitor, Pfizer). Five of the patients were assigned to dazoxiben and five to placebo.
Before treatment, the FSP at 10 °C in the patient groups was significantly lower than that in a normal reference group, but all rheologic variables, measured at 37 and 10 °C, were normal. There was no significant correlation between FSP and rheology. Dazoxiben did not yield any subjective relief or give any objective effect.